Grimbergen, Belgium

Winok Debyser

This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Danisco A/s, K.u. Leuven Research & Development. Active years: 2005-2008.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.1

ph-index = 1


Company Filing History:


Years Active: 2005-2008

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Winok Debyser: Innovator in Enzyme Inhibition

Introduction

Winok Debyser is a notable inventor based in Grimbergen, Belgium. He has made significant contributions to the field of enzyme inhibition, holding 2 patents that focus on innovative methods and applications.

Latest Patents

Debyser's latest patents include "Inhibitors of cellulolytic, xylanolytic and β-glucanolytic enzymes." This invention concerns an inhibitor of xylanolytic and/or β-glucanolytic enzymes, detailing methods for obtaining the inhibitor and its applications in various processes. Another significant patent is "Biocatalyst inhibitors," which outlines a method for the separation and/or isolation of inhibitors of cellulolytic, xylanolytic, and/or beta-glucanolytic enzymes, along with processes for enhancing or reducing the activity of these inhibitors.

Career Highlights

Throughout his career, Winok Debyser has worked with prominent companies such as Danisco A/S and KU Leuven Research & Development. His work has focused on advancing the understanding and application of enzyme inhibitors in various industries.

Collaborations

Debyser has collaborated with notable colleagues, including Jan Delcour and Kurt Gebruers, contributing to the advancement of research in enzyme inhibition.

Conclusion

Winok Debyser's innovative work in enzyme inhibition has led to valuable patents and collaborations, showcasing his impact in the field. His contributions continue to influence research and applications in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…